Id
|
Protein
|
PTM type
|
Site
|
Species
|
Disease
|
Celline
|
Drug
|
Regulatory
|
Score
|
Ref.
|
acc1251 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
SK-BR-3 |
Pelitinib |
Impairing |
5.0 |
21046231
|
acc1252 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
T47D |
Pelitinib |
Impairing |
5.0 |
21046231
|
acc1253 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
SK-BR-3 |
Canertinib |
Impairing |
5.0 |
21046231
|
acc1254 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
T47D |
Canertinib |
Impairing |
5.0 |
21046231
|
acc1255 |
beta-catenin |
phosphorylation |
Ser552 |
human |
Colorectal Cancer |
HCT116 |
Rp-8-Br-cAMPS |
Associated |
4.0 |
22168384
|
acc1256 |
beta-catenin |
phosphorylation |
Ser675 |
human |
Colorectal Cancer |
HCT116 |
Rp-8-Br-cAMPS |
Associated |
4.0 |
22168384
|
acc1257 |
cSrc |
phosphorylation |
Tyr416 |
human |
Breast Cancer |
MDA-MB-231 |
pHe |
Associated |
3.0 |
35538691
|
acc1258 |
cSrc |
phosphorylation |
Tyr416 |
human |
Breast Cancer |
LM3 |
pHe |
Associated |
3.0 |
35538691
|
acc1259 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H1155 |
Radiation |
Impairing |
4.5 |
11358816
|
acc1260 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H157 |
Radiation |
Impairing |
4.5 |
11358816
|
acc1261 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H157 |
Trastuzumab |
Impairing |
5.0 |
11358816
|
acc1262 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H157 |
Gemcitabine |
Impairing |
5.0 |
11358816
|
acc1263 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H1155 |
Etoposide |
Impairing |
5.0 |
11358816
|
acc1264 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H1155 |
CDDP |
Impairing |
5.0 |
11358816
|
acc1265 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H1155 |
Paclitaxel |
Impairing |
5.0 |
11358816
|
acc1266 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H1155 |
Trastuzumab |
Impairing |
5.0 |
11358816
|
acc1267 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H1155 |
Gemcitabine |
Impairing |
5.0 |
11358816
|
acc1268 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H1155 |
Radiation |
Impairing |
4.5 |
11358816
|
acc1269 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H157 |
Radiation |
Impairing |
4.5 |
11358816
|
acc1270 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H1703 |
Etoposide |
Impairing |
5.0 |
11358816
|
acc1271 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H1703 |
Etoposide |
Impairing |
5.0 |
11358816
|
acc1272 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H1703 |
CDDP |
Impairing |
5.0 |
11358816
|
acc1273 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H1703 |
Paclitaxel |
Impairing |
5.0 |
11358816
|
acc1274 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H1703 |
Trastuzumab |
Impairing |
5.0 |
11358816
|
acc1275 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H1703 |
Gemcitabine |
Impairing |
5.0 |
11358816
|
acc1276 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H157 |
Etoposide |
Impairing |
5.0 |
11358816
|
acc1277 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H157 |
CDDP |
Impairing |
5.0 |
11358816
|
acc1278 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H157 |
Paclitaxel |
Impairing |
5.0 |
11358816
|
acc1279 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H157 |
Trastuzumab |
Impairing |
5.0 |
11358816
|
acc1280 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H157 |
Gemcitabine |
Impairing |
5.0 |
11358816
|
acc1281 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H1155 |
Etoposide |
Impairing |
5.0 |
11358816
|
acc1282 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H1703 |
CDDP |
Impairing |
5.0 |
11358816
|
acc1283 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H1155 |
CDDP |
Impairing |
5.0 |
11358816
|
acc1284 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H1155 |
Paclitaxel |
Impairing |
5.0 |
11358816
|
acc1285 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H1155 |
Trastuzumab |
Impairing |
5.0 |
11358816
|
acc1286 |
AKT |
phosphorylation |
Thr308 |
human |
Lung Cancer |
H1155 |
Gemcitabine |
Impairing |
5.0 |
11358816
|
acc1287 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H1703 |
Paclitaxel |
Impairing |
5.0 |
11358816
|
acc1288 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H1703 |
Trastuzumab |
Impairing |
5.0 |
11358816
|
acc1289 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H1703 |
Gemcitabine |
Impairing |
5.0 |
11358816
|
acc1290 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H157 |
Etoposide |
Impairing |
5.0 |
11358816
|
acc1291 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H157 |
CDDP |
Impairing |
5.0 |
11358816
|
acc1292 |
AKT |
phosphorylation |
Ser473 |
human |
Lung Cancer |
H157 |
Paclitaxel |
Impairing |
5.0 |
11358816
|
acc1293 |
AKT |
phosphorylation |
Ser473 |
human |
Colorectal Cancer |
SW480 |
Phytomedicine |
Associated |
4.0 |
25647359
|
acc1294 |
AKT |
phosphorylation |
Ser473 |
human |
Colorectal Cancer |
DLD-1 |
Phytomedicine |
Associated |
4.0 |
25647359
|
acc1295 |
AKT |
phosphorylation |
Ser473 |
human |
Bladder Cancer |
T24 |
Gemcitabine |
Impairing |
5.0 |
33452459
|
acc1296 |
AKT |
phosphorylation |
Thr308 |
human |
Bladder Cancer |
T24 |
Gemcitabine |
Impairing |
5.0 |
33452459
|
acc1297 |
AKT |
phosphorylation |
Ser473 |
human |
Bladder Cancer |
UM-UC-3 |
Gemcitabine |
Impairing |
5.0 |
33452459
|
acc1298 |
AKT |
phosphorylation |
Thr308 |
human |
Bladder Cancer |
UM-UC-3 |
Gemcitabine |
Impairing |
5.0 |
33452459
|
acc1299 |
ERK1 |
phosphorylation |
Thr202 |
human |
Thyroid Cancer |
LOXIMVI |
AMG655 |
Enhancing |
5.0 |
25867065
|
acc1300 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Thyroid Cancer |
LOXIMVI |
AMG655 |
Enhancing |
5.0 |
25867065
|